新华鲜报丨用药利好事关你我！国家医保药品“清单”一览

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and patient benefits [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Scope - The payment scope has been broadened to include 65 drugs with new indications, such as additional targets for non-small cell lung cancer and expanded age eligibility for narcolepsy treatment [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the eligibility for certain drugs from "previous chemotherapy" to "prior chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that are clinically obsolete or no longer produced [6] - A transition period of six months has been established for patients to continue purchasing removed drugs at previous reimbursement standards [6] Group 5: Accessibility Features - The National Medical Insurance Bureau has launched a new feature on its WeChat account for users to query the updated basic medical insurance directory [6]